Skip to content
OpenEndo

Knowledge

Endometriosis, explained plainly

Treatments, diagnostics and research concepts — published from the open knowledge base, with sources and confidence.

Last reviewed

Sourced live from the openendo repository — updates automatically

Entitieshigh confidence

Ryeqo (relugolix combination)

Updated 2026-09-02

Oral GnRH-antagonist combination — one pill daily. See GnRH antagonists for endometriosis.

Key facts

  • EU-approved for symptomatic endometriosis: November 2023, for women with a history of previous medical or surgical treatment. (ema.europa.eu)
  • Available in Denmark with generelt tilskud (general reimbursement — automatic at the pharmacy). The Danish Medicines Agency (Lægemiddelstyrelsen) preserved general reimbursement for the endometriosis indication. (laegemiddelstyrelsen.dk)
  • Price in DK: ~849 DKK / 28 tablets (~28–30 DKK/day); 84-tablet packs ~2,411–2,416 DKK (medicin.dk, Sep 2026). (medicin.dk)
  • Prescribing: dispensing group NBS (gyn/obs) — specialist-prescribed. "Previous treatment" is interpreted by the reimbursement council as prior contraceptive-pill use.
  • Evidence (SPIRIT 1+2, n=1,261, 24 weeks): significantly more responders on dysmenorrhea and non-menstrual pelvic pain vs placebo; more women completely off analgesics at 24 weeks.
  • Add-back is built in (estradiol + NETA) — protects bone mineral density; aligns with DSOG guidance for GnRH analogues.

Why it matters

Ryeqo is currently the most accessible new treatment in Denmark for endometriosis after standard hormones have failed — approved, reimbursed, and pharmacy-available.

Related

Yselty (linzagolix) · GnRH antagonists for endometriosis · Ryeqo vs Yselty

Open the source page
Entitieshigh confidence

Yselty (linzagolix)

Updated 2026-09-02

Oral GnRH-antagonist. See GnRH antagonists for endometriosis.

Key facts (verified 2026-09-02)

  • EU approval, uterine fibroids: 14 June 2022 (central procedure).^[EMA]
  • EU approval, endometriosis: 20 December 2024 — "symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis" (CHMP positive October 2024). Same second-line positioning as Ryeqo (relugolix combination).^[Theramex EC announcement]
  • Endometriosis dose (EU SmPC): 200 mg once daily with hormonal add-back therapy (estradiol 1 mg / norethisterone acetate 0.5 mg), taken continuously. The 100 mg-no-add-back flexibility exists only on the fibroid label.^[EMA product information]
  • Evidence — EDELWEISS 3 (+ EDELWEISS 6 extension): 484 women with surgically confirmed endometriosis, randomised to placebo, Yselty 75 mg, or Yselty 200 mg + ABT. Dysmenorrhea responders: 72.9% vs 23.5% placebo at month 3 (OR 8.80; 97.5% CI 4.86–15.91), sustained at month 12 (91.0%). Non-menstrual pelvic pain responders: 47.3% vs 30.9% (OR 2.01).^[EMA product information §5.1]
  • The 75 mg monotherapy arm also separated from placebo (published analysis: 44.0% dysmenorrhea responders) (doi.org) — but 75 mg is not a marketed endometriosis dose.
  • ~98.6% of EDELWEISS participants were White; efficacy evidence in non-White populations is thin (see the diversity gap in the M2 digest).
  • England: NICE guidance TA1067 recommends linzagolix as an option for endometriosis symptoms.^[NICE]

Denmark — verified status (2026-09-02)

  • Authorised in Denmark via the EU central procedure. Lægemiddelstyrelsen expected it on the Danish market from September 2024; dispensing group NBS (specialist gyn/obs).^[Medicintilskudsnævnet indstilling]
  • Reimbursement: generelt klausuleret tilskud (decision process Nov–Dec 2023) covers uterine fibroids only, with a clause — patients with moderate-to-severe fibroid symptoms where GnRH-antagonist combined with norethisterone/estrogen (with general, unclaused reimbursement) is not medically appropriate. The doctor must write "tilskud" on the prescription.^[Medicintilskudsnævnet indstilling]
  • No general reimbursement for the endometriosis indication as of 2026-09-02 — no Lægemiddelstyrelsen decision found. Endometriosis treatment is therefore out-of-pocket at the pharmacy, unless the region grants enkelttilskud (individual reimbursement) on application — ask the specialist.
  • Danish list price is not published in the LMS documents (confidential). UK list price ~£1,100/year (NICE). Check the current Danish pack price before relying on cost estimates.

Why it matters

For Danish endometriosis patients, Ryeqo (relugolix combination) is the reimbursed first choice. Yselty matters when add-back-containing GnRH-antagonist therapy is unsuitable — but for the endometriosis indication it currently means full price, specialist prescription, and a pharmacy-level availability check. Verify current stock and price with the pharmacy before planning around it.

Related

Ryeqo (relugolix combination) · GnRH antagonists for endometriosis · Ryeqo vs Yselty

Open the source page
Entitiesmedium confidence

HMI-115 (anti-prolactin-receptor antibody)

Updated 2026-09-02

First-in-class anti-prolactin-receptor monoclonal antibody — the first non-hormonal therapy for endometriosis to reach Phase 3.

Key facts

  • Mechanism: blocks prolactin-receptor signalling implicated in endometriosis lesion growth — no hormonal suppression, so no menopausal side effects.
  • Phase 2: significant pain reduction vs placebo without menopausal side effects (published in Lancet Obstetrics, Gynaecology & Women's Health). (prnewswire.com)
  • Phase 3: first patient dosed March 2026 (China); NCT07318688. FDA Fast Track designation. (clinicaltrials.gov)
  • Status confidence: medium — pipeline claims from company materials; independent replication pending.

Why it matters

If Phase 3 confirms Phase 2, this is the first fundamentally new treatment mechanism for endometriosis in decades — an alternative for women who cannot or will not take hormones. Realistic EU/DK timeline: earliest ~2029 if all goes well. Do not count on it today.

Related

GnRH antagonists for endometriosis · Ryeqo vs Yselty · Saliva diagnostics for endometriosis

Open the source page
Entitieshigh confidence

MY-ENDO trial (NCT06211231)

Updated 2026-09-02

"Mind Your ENDOmetriosis." A non-drug clinical study testing whether a digital mindfulness- and acceptance-based programme improves quality of life, work ability, pain and mental/physical health in people with endometriosis. Run by Aarhus University with Aarhus University Hospital and the Danish endometriosis patient organisation. (clinicaltrials.gov)

Featured on the OpenEndo homepage under "Take action" — recruiting in Denmark. (openendo.org)

Trial facts (ClinicalTrials.gov, 2026-09-02)

Field Value
NCT ID NCT06211231
Status Recruiting (registered primary completion Dec 2025 — contact the study team for current status)
Target enrolment 255 participants
Sex / age Female, ≥ 18 years
Primary outcome Endometriosis-related quality of life
Locations Aarhus University Hospital, Dept. of Gynaecology & Obstetrics · Danish Endometriosis Patients Association (Billund)

Who can join (plain-language summary)

Inclusion:

  • ≥ 18 years, informed consent.
  • Endometriosis diagnosed by a gynaecologist (medical history, ultrasound, laparoscopy or MRI — self-reported at screening).
  • Moderate-to-severe symptoms: pelvic pain or fatigue > 2 on the 0–10 scale, or reduced endometriosis-related quality of life (EHP-30 subscale ≥ 40).
  • Relevant medical and/or surgical treatment per ESHRE guidelines must already have been tried.
  • Willing to practise mindfulness and yoga at home 30–45 minutes, 5–7 days a week during the treatment period.

Exclusion:

  • Severe psychiatric diagnosis (made by a psychiatrist) or ongoing psychiatric treatment.
  • Pregnancy, or planned pregnancy during the study.
  • Circumstances that would block participation: major life events (e.g. divorce, bereavement) or linguistic/cultural barriers.

Why it matters

Most endometriosis trials test drugs. MY-ENDO tests a non-drug, digital self-management tool — directly relevant to the hub's patient-first agenda, and a rare Danish recruiting option for people who have already tried guideline treatment and still live with pain/fatigue. It complements (does not replace) medical care. (clinicaltrials.gov)

Talk to your gynaecologist or the study team before deciding. Registry data for this trial is also in the site's weekly dataset. (raw.githubusercontent.com)

Related

Ryeqo (relugolix combination) · GnRH antagonists for endometriosis · Saliva diagnostics for endometriosis

Open the source page
Entitiesmedium confidence

Sirolimus (rapamycin)

Updated 2026-09-14

Oral mTOR inhibitor (macrolide immunosuppressant). Rank 1 (TOP TIER) in OpenEndo's M3 repurposing screen for endometriosis — as a research priority, not a treatment recommendation. See Computational drug repurposing for endometriosis.

What it is

  • Approved for renal-transplant rejection prophylaxis and lymphangioleiomyomatosis (LAM). (ema.europa.eu) Cancer indications belong to the rapalog everolimus/temsirolimus, not sirolimus itself.
  • Mechanism: sirolimus binds the immunophilin FKBP12, and the sirolimus–FKBP12 complex inhibits mTORC1. The M3 ChEMBL screen hit (pchembl 8.38 vs FKBP4, CHEMBL4050) reflects binding promiscuity across the FKBP family — it is not the drug's patient-facing pharmacology.
  • Naming note: FKBP4 (gene) = FKBP52 (protein); FKBP5 = FKBP51. Sirolimus binds FKBP12 (gene FKBP1A), a different family member.

Why it surfaced (M3)

The screen pairs approved drugs with measured potency against novel endometriosis targets. The FKBP4 pair is mechanistically interesting — FKBP52 is the progesterone-receptor co-chaperone that enhances PR transcriptional activity, and PR resistance is central to endometriosis — but sirolimus ranks on its own mechanism (mTOR), which has independent endometriosis evidence. (raw.githubusercontent.com)

Endometriosis evidence (verified 2026-09-02; registry re-checked 2026-09-14)

  • Review: mTOR pathway is activated in endometriosis; mTOR inhibitors show efficacy as monotherapy in models and may relieve hormonal-therapy resistance — narrative review, Mol Hum Reprod 2024. (pubmed.ncbi.nlm.nih.gov)
  • Animal model: rapamycin reduces endometriosis lesions in mice, Exp Ther Med 2016. (pubmed.ncbi.nlm.nih.gov)
  • Infertility + ovarian senescence: in a mouse endometriosis model, rapamycin improved endometriosis-related infertility via the PPARα/IGFBP2 pathway — reduced ovarian senescence markers (p16, p21, γH2AX) and oxidative stress, improved ovarian/fertility endpoints, Mol Med Rep 2026. (pubmed.ncbi.nlm.nih.gov)
  • Human corollary (retrospective): in an IVF cohort of 168 endometriosis patients (80 treated), 3 months of rapamycin lowered senescence/oxidative markers in follicular fluid and improved oocyte/fertilization outcomes, Reprod Biomed Online 2024. No trial registration reported; reflects off-label use in one centre. (pubmed.ncbi.nlm.nih.gov)
  • Pathway context (2025–2026, not sirolimus trials): S1PR4 promotes ectopic stromal-cell viability, invasion and glycolysis via mTOR signalling, with the mTOR inhibitor AZD8055 used as a pathway tool in vitro. (pubmed.ncbi.nlm.nih.gov) A preliminary Iranian case–control study reported associations between PIK3CA / AKT1 / mTOR SNPs and endometriosis susceptibility. (pubmed.ncbi.nlm.nih.gov) These support pathway relevance; they do not upgrade clinical evidence for sirolimus.
  • No registered interventional trial of rapamycin/sirolimus/everolimus/ temsirolimus/or “mTOR” as intervention in endometriosis (or endometrioma) on ClinicalTrials.gov — re-queried API v2 on 2026-09-14 (0 hits; dienogest control still 40). Novelty remains high; clinical trial evidence remains absent. (raw.githubusercontent.com)

The FKBP4/progesterone-resistance link (separate axis — do not conflate)

FKBP52 (FKBP4) governs normal PR function: FKBP52 deficiency confers uterine progesterone resistance in vivo, (pubmed.ncbi.nlm.nih.gov) and Fkbp52⁻/⁻ mice develop progesterone-resistant endometriosis with enhanced lesion growth. (pubmed.ncbi.nlm.nih.gov) In women, FKBP4 mRNA is reduced in the endometrium of endometriosis patients, in part via HOXA10 (pubmed.ncbi.nlm.nih.gov) and miR-29c (pubmed.ncbi.nlm.nih.gov) — a plausible contributor to progesterone resistance.

Uncertainty flag: restoring FKBP4 is a different drug problem than mTOR inhibition. Phase 1.0 docking (2026-09-04) showed rapamycin can engage FKBP52 (−6.38 kcal/mol vs FKBP12 −7.06), which is consistent with ChEMBL binding promiscuity, but that does not mean sirolimus clinically restores PR signalling. Keep mTOR (TOP TIER) and FKBP4/PR-resistance as linked-but-separate research notes.

Expression cross-check (GTEx/HPA + GEO reanalysis)

FKBP4 is strongly expressed in normal endometrium (HPA consensus nTPM 30.6, IHC high; GTEx uterus 43.5 TPM) and reduced — not absent — in disease. The target is present at the disease site. Full table: docs/research/evidence/m3-validation.md. (proteinatlas.org)

GEO reanalysis (GSE282532; 5 paired eutopic/ectopic RNA-seq; Peking University First Hospital, public Nov 2025) confirms FKBP4 is 2.2x lower in ectopic lesions (mean 32.5 vs 14.6 FPKM; FC 0.45; consistent across all 5 pairs). This independently confirms the HOXA10/miR-29c literature and validates that FKBP4 reduction is a lesion-level feature, not an artifact of bulk-tissue comparison. Source: NCBI GEO, GSE282532 (2026-09-03). (ncbi.nlm.nih.gov)

Caveats

  • Chronic immunosuppression, teratogenicity and drug-drug interactions make systemic sirolimus a heavy intervention for a benign chronic disease.
  • Evidence is preclinical + one retrospective cohort + pathway genetics — hypothesis-generating research output, never treatment advice. Talk to a specialist about actual endometriosis care (e.g. GnRH antagonists for endometriosis such as Ryeqo (relugolix combination)).
  • Phase 2 MD (FKBP12 crystal RAP control → FKBP52 Vina pose) remains blocked on GPU budget — docking alone does not settle pose claims. Partner-ready mTOR PD spec (no GPU): docs/research/lab-protocols/01-sirolimus-mtor-fkbp4-pr.md.

Related

Computational drug repurposing for endometriosis · GnRH antagonists for endometriosis · Ryeqo vs Yselty · MRGPRX2 — mast-cell pain axis in endometriosis · Ferroptosis in endometriosis

Open the source page
Conceptshigh confidence

GnRH antagonists for endometriosis

Updated 2026-09-02

Oral, reversible suppression of the pituitary-gonadal axis. Unlike older GnRH agonists (which flare first), antagonists suppress estradiol quickly and reversibly — and unlike agonists, they can be taken as a daily pill.

How it works

  • Blocks GnRH receptors → rapid drop in estradiol → endometriosis lesions starve and shrink.
  • Add-back therapy (low-dose estradiol + progestin) protects bone mineral density and reduces hot flushes — built into Ryeqo (relugolix combination), optional with Yselty (linzagolix).
  • Full suppression is not required for pain relief: partial suppression (75 mg linzagolix) works and preserves more estradiol — relevant for younger women.

Evidence position

  • Ryeqo: SPIRIT 1+2 (n=1,261) — significant, clinically meaningful response; reimbursed in DK.
  • Yselty: EDELWEISS 3 + 6 (n=486 + 353) — significant; 75 mg option without add-back; NICE recommended.
  • Class caveat: both are "after previous medical or surgical treatment" — i.e. second-line after standard hormones, not first-line.

Open questions

  • Head-to-head vs progestins/estroprogestins is largely missing (EDELWEISS 6 authors note this). (read.qxmd.com)
  • Long-term (multi-year) bone and metabolic safety data still accumulating.

Related

Ryeqo (relugolix combination) · Yselty (linzagolix) · Ryeqo vs Yselty · HMI-115 (anti-prolactin-receptor antibody)

Open the source page
Conceptsmedium confidence

Saliva diagnostics for endometriosis

Updated 2026-09-20

WHO reports a typical time to diagnosis of 4–12 years (a range: “the average time to diagnosis is between 4 and 12 years” — not a single-year mean). (who.int) Endometriosis affects an estimated 10% (190 million) of reproductive-age women worldwide (same fact sheet). This page is research/advocacy context, not medical advice.

Definitive diagnosis remains surgical (laparoscopy with visualisation and/or histology) where a tissue-level confirmation is required. Expert ultrasound/MRI can support a clinical diagnosis. Saliva-based molecular testing is an emerging adjunct, not an established diagnostic standard.

The test

  • Ziwig Endotest: saliva sample → microRNA profiling + AI → result in ~1 week. CE-IVD marked, prescription-based, marketed sensitivity >97% / specificity >93% (manufacturer claims; independent validation varies — do not repeat percentages as settled). (ziwig.com)
  • Available in Denmark via Life Genomics (Sweden): +46 708-112 152, info@lifegenomics.se. Private-pay (price on enquiry). Useful when the diagnosis is still unclear — can short-circuit years of referrals.

Policy watch (2026-09)

BMJ news (Wise J, 16 Sep 2026, PMID 42749315, DOI 10.1136/bmj-2026-100876) reports NICE recommending a single saliva test to speed diagnosis in primary care. NCBI-verified; the PubMed record is title-level only (no abstract, no accuracy figures). Treat as NICE draft / early-use, emerging — not established NHS standard. Cite primary accuracy papers, not the news item, before repeating any performance claim. (pubmed.ncbi.nlm.nih.gov)

Validation landscape

  • GynRNA study (ZIWIG, NCT06392997): validating salivary RNA against surgical findings — recruiting. (clinicaltrials.gov)
  • EUmetriosis (Horizon Europe) is developing steroid-metabolomics + miRNA diagnostics.

Caveats

  • Not a diagnostic standard; treat as an adjunct, not a replacement for clinical work-up or surgery when definitive diagnosis is needed.
  • Reimbursement: not covered by Danish public insurance — out-of-pocket.
  • No established blood-test standard for endometriosis; emerging saliva tests do not change that until independently validated and commissioned.

Related

Ryeqo vs Yselty · HMI-115 (anti-prolactin-receptor antibody) · GnRH antagonists for endometriosis

Open the source page
Conceptsmedium confidenceContested — sources disagree

Ferroptosis in endometriosis

Updated 2026-09-14

Ferroptosis is a regulated, iron-dependent form of cell death driven by lipid peroxidation. Two of its best-known gatekeepers are GPX4 (glutathione peroxidase 4) and SLC7A11 (the cystine/glutamate antiporter xCT). Because endometriosis lesions bleed, accumulate iron and face oxidative stress, ferroptosis has become an active research question in the field. (pubmed.ncbi.nlm.nih.gov)

Why it surfaced for OpenEndo

  • SEMA3C → ferroptosis: a 2026 paper reports that SEMA3C promotes endometriosis progression by inducing ferroptosis (and enhancing lesion survival). (pubmed.ncbi.nlm.nih.gov) A review of autophagy and ferroptosis in endometriosis was published the same period. (pubmed.ncbi.nlm.nih.gov)
  • Direct overlap with OpenEndo's target audit: both GPX4 and SLC7A11 are among the 35 novel drug targets (no known drug mechanisms in ChEMBL) in the M1 fold-input pack.
  • M3 screen convergence: the ChEMBL-based repurposing screen flags sulfasalazine (an approved xCT/SLC7A11 inhibitor) against SLC7A11 — the same axis the mechanism literature points at. Hypothesis-generating, not clinical. (raw.githubusercontent.com)
  • Further induction confirmation (digest-2026-09-11): FIN56 suppressed ectopic lesion growth in vitro/in vivo by raising mitochondrial ROS and lipid peroxidation via an ACACA/ARID5A/NOX4 axis. (pubmed.ncbi.nlm.nih.gov)

Direction of effect — resolved lean with contested nuance (MEDIUM)

Detailed verdict: docs/research/evidence/ferroptosis-direction.md. In short: ferroptosis is compartment-dependent — in lesion epithelial/stromal cells it is a growth brake that lesions actively evade (MGST3, HSD11B1, FZD7→SLC7A11 up-regulation), and forcing it back on (erastin, andrographolide, FIN56, xCT blockade) reproducibly shrinks lesions in 2025–2026 models; but ferroptosis striking lesional CD8⁺ T cells disables anti-lesion immunity and helps the lesion, (pubmed.ncbi.nlm.nih.gov) and ferroptosis in eutopic endometrium harms decidualization/fertility. (pubmed.ncbi.nlm.nih.gov) The SEMA3C finding is sub-lethal ferroptotic signaling exploited by lesion cells, not evidence that lethal ferroptosis drives lesions. For the M3 screen this supports the therapeutic direction of SLC7A11/xCT inhibition in lesion cells (sulfasalazine), while flagging that systemic (non-lesion-targeted) induction carries immune-cell and fertility risks — one reason sulfasalazine stays WATCHLIST.

Additional 2025–2026 mechanism papers (live PMIDs; preclinical / computational)

  • Estradiol–MBOAT1 regulation of ferroptosis in endometrial stromal cells and a mouse model. (pubmed.ncbi.nlm.nih.gov)
  • EGR1 promotes ferroptosis via transcriptional activation of HMOX1 (multi-GEO + validation). (pubmed.ncbi.nlm.nih.gov)
  • USP33 / ferritinophagy / Hippo–YAP: USP33 loss confers ferroptosis resistance in ectopic stromal cells. (pubmed.ncbi.nlm.nih.gov)
  • Bioinformatics nominating ferroptosis-related genes as diagnostic/predictive features. (pubmed.ncbi.nlm.nih.gov)

These enlarge the mechanistic map; none are sulfasalazine clinical trials.

Contested / host-protective claims (do not overwrite)

Two 2026 electroacupuncture mouse papers report suppressing ferroptosis (via Nrf2 / GPX4) with claimed benefit for ovarian function and for ectopic and eutopic endometrium. (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov) Uncertainty flag: if read as “ferroptosis is always bad in endometriosis,” they appear to conflict with lesion-cell induction studies (erastin, FIN56, MGST3/HSD11B1/FZD7–SLC7A11). OpenEndo’s working reconciliation is the existing compartment model: eutopic/ovarian ferroptosis can be host-harmful while lesion-cell ferroptosis remains a growth brake. EA is not an xCT pharmacology study and does not clear systemic sulfasalazine. contested: true until a clearer human/compartment synthesis is written.

Lesion-expression corroboration (GEO reanalysis, 2026-09-03/04)

Lesional transcriptomics (3 datasets; methods: docs/research/virtual/phase0.5.md) support the "lesions evade ferroptosis" read at the expression level:

  • GSE282532 (endometrioma bulk, 5 patient-paired): SLC7A11 2× down and ACSL4 2.4× down in ectopic vs eutopic tissue — ferroptosis evasion via suppression of effector genes, not overexpression of the SLC7A11 resistance node. (ncbi.nlm.nih.gov)
  • GSE247695 (scRNA-seq) + GSE263897 (GeoMx spatial): SLC7A11 down / no constitutive up-regulation in lesion compartments — consistent across platforms. (ncbi.nlm.nih.gov) (ncbi.nlm.nih.gov)

Implication for the M3 screen: xCT inhibition (sulfasalazine) targets a transporter the lesion often keeps low — consistent with the therapeutic direction (forcing ferroptosis back on), while low lesional expression underlines that selectivity/toxicity, not target presence, is the open question. Phase 1.0 docking (2026-09-04, PR #22) confirms sulfasalazine binds the xCT substrate cavity (−8.52 vs native −9.35 kcal/mol).

Registry / clinical status (re-checked 2026-09-14)

ClinicalTrials.gov API v2: 0 endometriosis interventional trials for sulfasalazine, erastin, or “ferroptosis” as intervention (dienogest control still 40). No human trial readout moves the WATCHLIST status. (raw.githubusercontent.com)

Caveats

  • Mechanism science is 2025–2026 and largely preclinical; clinical evidence in endometriosis is absent (no registered xCT-inhibitor trial).
  • Cell type and lesion stage matter: induction vs inhibition is not a one-size answer across compartments (lesion stroma/epithelium vs CD8⁺ T cells vs eutopic endometrium / ovary).
  • In-vitro potency ≠ clinical efficacy; nothing here is treatment guidance.
  • Systemic sulfasalazine doses that engage xCT carry historical toxicity baggage (see m3-validation.md); lesion-local delivery remains the open translational question. Partner-ready selectivity spec: docs/research/lab-protocols/03-ferroptosis-selectivity-coculture.md.

Related

Computational drug repurposing for endometriosis · GnRH antagonists for endometriosis · Sirolimus (rapamycin) · MRGPRX2 — mast-cell pain axis in endometriosis

Open the source page
Conceptsmedium confidence

Computational drug repurposing for endometriosis

Updated 2026-09-04

The idea: approved drugs already have known safety profiles. Screening them against disease biology can shortcut the 10–15 year de-novo pipeline — attractive for a disease like endometriosis where dedicated drug development is underfunded.

OpenEndo's program runs two complementary approaches:

1. Transcriptomics-based (expression side)

A 2026 iScience proof-of-concept pipeline over approved drugs flagged simvastatin (statin; anti-inflammatory/anti-angiogenic) and primaquine (anti-malarial; oxidative stress) as endometriosis candidates from transcriptomic signatures. (pubmed.ncbi.nlm.nih.gov) This is the template for expression-driven repurposing: replicate hits against independent expression data (GTEx/GEO) before clinical follow-up.

2. Target-activity-based (our M3 screen)

A ChEMBL screen over the 35 novel targets (approved drugs, max phase 4, measured potency pChEMBL ≥ 6) produced 9 candidate pairs. (raw.githubusercontent.com) Highlights:

Target Approved drug(s) Why it matters
SLC7A11 Sulfasalazine xCT inhibitor — converges with the Ferroptosis in endometriosis mechanism literature
FKBP4 Sirolimus, tacrolimus, cyclosporine Progesterone-receptor chaperone; endometriosis is progesterone-resistant
MRGPRX2 Cetrorelix GnRH-antagonist class already used clinically — target validity support
GPER1 Estradiol Rapid-signaling estrogen receptor in an estrogen-driven disease
ACVR1B Crizotinib, dabrafenib TGF-β/activin signaling (fibrosis, lesion growth)
SLCO2A1 Dinoprostone (PGE2) Prostaglandin transporter — direction of effect needs review

Validation ladder

  1. Cross-reference target expression in endometriosis tissue (GTEx/GEO).
  2. Mechanism + direction-of-effect review per pair.
  3. In-vivo / clinical follow-up only after 1–2.

In-vitro potency ≠ efficacy; the screen is hypothesis generation, and nothing here is treatment guidance. Current focus: depth-check each candidate (evidence, safety, novelty) → ranked shortlist. (raw.githubusercontent.com)

Related

Ferroptosis in endometriosis · GnRH antagonists for endometriosis · Ryeqo vs Yselty

Open the source page
Conceptsmedium confidence

MRGPRX2 — mast-cell pain axis in endometriosis

Updated 2026-09-20

MRGPRX2 (Mas-related G-protein-coupled receptor X2) is a mast-cell receptor increasingly implicated in endometriosis pain. It surfaced in OpenEndo's M3 repurposing screen as the ChEMBL target hit for cetrorelix — a pair that turned out to be target-validating (build an antagonist), not a repurposing case. See Computational drug repurposing for endometriosis.

The pain mechanism (2025, FASEB J)

A 2025 study (FASEB J, PMID 40600649) reports the axis end-to-end: MRGPRX2⁺ mast-cell density is increased in endometriotic lesions; endometriotic cells release HBD-2 (β-defensin 2), which triggers MRGPRX2-dependent histamine release from mast cells; histamine then sensitizes dorsal-root-ganglion sensory neurons via HRH1/TRPV1 signalling, driving pain/hyperalgesia. Mast-cell knockout, MRGPRX2 deficiency and H1 blockade each relieved the phenotype in models. (pubmed.ncbi.nlm.nih.gov) (First published 2025 — earlier OpenEndo notes dated it 2026; corrected 2026-09-02.)

Background: mast cells, histamine, and endometriosis pain

Mast cells accumulate in peritoneal, ovarian and deep infiltrating lesions, often near nerves, in pain-associated patterns (Anaf 2006); (pubmed.ncbi.nlm.nih.gov) they are present in peritoneal fluid of endometriosis patients; (pubmed.ncbi.nlm.nih.gov) and recent reviews position mast cells and oestrogen-driven histamine/FGF2 release at the centre of pain sensitization. (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov)

2025–2026 additions (live PMIDs):

  • A 2025 review frames endometriosis pain as neuroinflammation converging on JAK/STAT signalling and mast-cell activation, and discusses JAK inhibitors and mast-cell stabilizers as candidate repurposing directions — adjacent to, not substituting for, MRGPRX2 antagonism. (pubmed.ncbi.nlm.nih.gov)
  • A 2025 histamine-landscape study reports elevated HDC and inflammatory/ neurotrophic mediators across peritoneal, deep and ovarian lesions, with HRH1–HRH4 protein on epithelial, immune and nerve structures (transcript levels of the receptors themselves not differentially expressed). (pubmed.ncbi.nlm.nih.gov) This supports the histamine arm downstream of the MRGPRX2 axis without itself proving MRGPRX2 antagonism.

The M3 hit: cetrorelix → MRGPRX2 (measured, but agonism)

  • Measured activity (real): cetrorelix (CHEMBL1200490, max phase 4) has two ChEMBL activities against MRGPRX2 (CHEMBL5849) — EC50 617 nM / pChEMBL 6.21 (Ca²⁺ FLIPR) and EC50 813 nM / pChEMBL 6.09 (β-arrestin PRESTO-Tango), from probe-design/off-target profiling (Lansu et al., Nat Chem Biol 2017). (pubmed.ncbi.nlm.nih.gov)
  • But the measured effect is agonism — activating MRGPRX2, the opposite of what the pain axis above would need. No clinical link between cetrorelix and mast-cell/MRGPRX2 action exists.
  • Cetrorelix (Cetrotide) is an established GnRH antagonist used in endometriosis — the 3 mg once-weekly × 8-week regimen is documented in two small 2002 German reports (15 patients each). (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov) Registry (re-checked ClinicalTrials.gov API v2, 2026-09-14): still 2 endometriosis-linked cetrorelix studies (NCT00244452 phase-2 SR endometriosis; NCT04071574 ICSI stimulation protocol listing a GnRH antagonist) — and 0 trials naming MRGPRX2 as intervention/target. (raw.githubusercontent.com)
  • Conclusion: the M3 pair validates MRGPRX2 as an endometriosis-relevant target (lesional mast cells + pain readout) but does not make cetrorelix a repurposing lead. The actionable direction is MRGPRX2 antagonist development for non-hormonal endometriosis pain.

Expression cross-check (GTEx/HPA + GEO reanalysis)

Bulk-tissue RNA is essentially zero (HPA endometrium nTPM 0.0, "not detected"; GTEx uterus 0.06 TPM) — expected for a receptor on a rare cell type (mast cells; also subsets of immune cells and dorsal root ganglion). The receptor is genuinely present at the lesion on infiltrating mast cells, which bulk screens cannot see. (proteinatlas.org)

GEO reanalysis of GSE282532 (5 paired eutopic/ectopic RNA-seq samples; Peking University First Hospital, public Nov 2025) corroborates this: MRGPRX2 is below detection in all eutopic and nearly all ectopic bulk samples, but canonical mast-cell markers are 11-15x enriched in ectopic lesions across all 5 pairs — CPA3 (13.6x), TPSAB1 (15.0x), TPSB2 (11.0x). This provides independent quantitative support for elevated mast-cell density in lesions. Source: NCBI GEO, GSE282532 (2026-09-03). (ncbi.nlm.nih.gov)

Uncertainty flag (lesion-type split): GSE247695 (scRNA) and GSE263897 (GeoMx spatial) did not show mast-cell / MRGPRX2 enrichment in superficial peritoneal lesions (markers at/under negative-probe background). OpenEndo currently reads this as endometrioma vs peritoneal lesion-type difference, not assay failure (phase0.5.md / m3-validation.md). Until more lesion-stratified human data exist, do not generalise endometrioma mast enrichment to all disease forms. Partner-ready IHC spec: docs/research/lab-protocols/02-mrgprx2-ihc-mast-cell-stratification.md.

Why it matters

Most endometriosis treatments are hormonal. A mast-cell/MRGPRX2 pain axis is a non-hormonal, mechanism-specific target for the pain that dominates the patient experience — relevant to the WHO 4–12-year typical time-to-diagnosis mission only insofar as better-targeted research shortens the path to real options. Hypothesis-generating research output; not medical advice. Cetrorelix→MRGPRX2 peptide docking remains deferred to Phase 2 (tool boundary).

Related

Computational drug repurposing for endometriosis · GnRH antagonists for endometriosis · Sirolimus (rapamycin) · Ferroptosis in endometriosis

Open the source page
Conceptshigh confidence

Diversity Gap in Endometriosis Research

Updated 2026-09-20

Endometriosis affects an estimated 190 million people of reproductive age worldwide, yet the evidence base that informs diagnosis and treatment has been built primarily on White, Western, high-income-country populations. This under-representation of racial, ethnic, socioeconomic and geographic diversity in research cohorts and clinical trials is the diversity gap — a structural problem with direct consequences for diagnosis equity, treatment access and scientific validity.

Historical framing: "a White woman's disease"

Early epidemiological literature described endometriosis as more prevalent in White women and rare in Black and Asian women — a claim that influenced clinical heuristics for decades. A 2019 review in AJOG revisited this framing and found it rested on methodological and social bias rather than biology: the studies that established the race-prevalence association used hospital registry data collected at a time when Black women had systematically less access to specialist care and laparoscopic diagnosis. (pubmed.ncbi.nlm.nih.gov) The review concluded there is no established biological basis for a racial difference in susceptibility; observed disparities are better explained by differential access to diagnosis. (pubmed.ncbi.nlm.nih.gov)

A 2017 IVF-cohort study found a higher prevalence of endometriosis among Asian women than White women in the same clinical setting, and endometriosis diagnosis did not worsen IVF outcomes regardless of ethnicity — illustrating that apparent "racial" patterns shift depending on access to care. (pubmed.ncbi.nlm.nih.gov)

Clinical trial representation

A 2025 BJOG analysis examined racial and ethnic representation in clinical trials that supported FDA approval of endometriosis treatments. The study found significant under-representation of non-White participants relative to disease burden, meaning approved therapies have limited evidence for their safety and efficacy profiles in the full patient population. (pubmed.ncbi.nlm.nih.gov) This is not a minor gap: pharmacokinetic, comorbidity and pain-phenotype differences can interact with treatment response in ways a homogeneous trial population cannot detect.

Lived experience: Black women with endometriosis in the US

A 2025 qualitative study (BMC Women's Health) interviewed 16 Black women in the US diagnosed with endometriosis. Participants described a pattern of dismissed symptoms, delayed diagnosis and poor patient-provider communication — consistent with the broader literature on medical racism, but compounding the already long endometriosis diagnostic delay (WHO typical time to diagnosis 4–12 years). (pubmed.ncbi.nlm.nih.gov) (who.int) Themes included feeling that their pain was not believed and difficulty navigating specialist referral systems. The study highlights that the diversity gap is not only a data problem but a care-delivery problem.

Socioeconomic and geographic dimensions

A 2024 multinational study (Pain journal) of women with endometriosis from Latin America and Spain found high pain-catastrophizing scores and significant variation in pain perception associated with socioeconomic factors and self-identified race. (pubmed.ncbi.nlm.nih.gov) The study underscored that endometriosis phenotype — particularly pain burden — is modulated by context factors largely invisible to trials conducted in high-income Western settings.

Why it matters for OpenEndo

The diversity gap is directly relevant to the OpenEndo mission in two ways:

  1. Data collection signals — the OpenEndo data pipeline should track participant diversity (race/ethnicity, country, socioeconomic setting) when ingesting study metadata. Studies that restrict their sample to a single demographic should be flagged and their findings qualified.

  2. Translation agenda — making research outputs available in multiple languages (patient tools, trial information, knowledge pages) is not cosmetic: it is evidence-backed advocacy for the communities most underserved by current research. The weekly digest notes (2026-09-01) that the diversity gap paper directly supports OpenEndo's multilingual access agenda.

Open questions

  • Does the diversity gap in trial populations affect the apparent efficacy of currently approved drugs (GnRH antagonists, progestins) in non-White and lower-income-country settings? Confidence: low — no comparative effectiveness data available.
  • Are there differences in Ferroptosis in endometriosis or mTOR-pathway activity across ancestry groups that would affect Computational drug repurposing for endometriosis candidate translation? Unknown; would require ancestry-stratified transcriptomic studies.

Related pages

Sources

PMID Authors Year Title
30738028 Bougie et al. 2019 Behind the times: revisiting endometriosis and race (AJOG)
40928122 Meyer et al. 2025 Disparities in Racial and Ethnic Representation in Clinical Trials for FDA-Approved Treatments of Endometriosis (BJOG)
40841635 Rice et al. 2025 "It's like your body is fighting against you": QOL in U.S. Black women with endometriosis (BMC Women's Health)
38564184 Flores et al. 2024 Moderators of pain perception: sociodemographics, racial self-identity, pain catastrophizing in Latin America/Spain (Pain)
28417349 Yamamoto et al. 2017 Higher prevalence in Asian women does not contribute to poorer IVF outcomes (J Assist Reprod Genet)
Open the source page
Conceptshigh confidence

Danish Registries for Endometriosis Research

Updated 2026-09-20

Denmark maintains a set of nationwide administrative and clinical registers that together form one of the world's richest data infrastructures for population-scale health research. For endometriosis, these registers are particularly valuable: the disease has a long diagnostic delay (WHO typical time to diagnosis 4–12 years), (who.int) affects a large fraction of reproductive-aged women, and has poorly understood long-term systemic consequences — all questions that require large, unselected, longitudinal cohorts. Despite this potential, Danish registry data has been underutilised for endometriosis to date, and the validation of key diagnostic codes is still recent work.

Key registers

Register Content Coverage
Danish National Patient Register (DNPR / LPR) Hospital diagnoses (ICD-10), procedures, outpatient contacts Nationwide, 1977-present
Danish Medical Birth Registry (MBR) Births, maternal diagnoses, obstetric outcomes Nationwide, 1973-present
Danish Prescription Register All redeemed prescriptions (ATC code, date, pharmacy) Nationwide, 1994-present
Danish Psychiatric Central Research Register Psychiatric diagnoses + contacts Nationwide, 1969-present
Danish Civil Registration System (CPR) Linkage key — all Danish residents have a unique CPR number Nationwide, 1968-present
Cause of Death Register Mortality causes Nationwide, 1970-present

All registers are linkable via the CPR number (anonymised for research), enabling multi-register cohort designs without additional recruitment or consent burden. Statistics Denmark manages access for approved research projects.

Validity of the endometriosis diagnosis code

The DNPR uses ICD-10 N80.x codes for endometriosis. A 2025 validation study (Thomsen et al., Eur J Obstet Gynecol) assessed the positive predictive value (PPV) of endometriosis codes in the DNPR for the period 1995–2018 using a sample of 300 patient records. (pubmed.ncbi.nlm.nih.gov) This study is the prerequisite for any register-based endometriosis research: without knowing the PPV, observed associations may be confounded by misclassification. The finding that overall data quality in the DNPR is high, but that code accuracy varies across ICD chapters and time periods, means researchers must account for period-specific PPV when using historical data.

What Danish registry research has found

Diagnostic delay in healthcare utilization

A 2023 Danish case-control study (Melgaard et al., Human Reproduction) showed women later diagnosed with endometriosis had significantly higher healthcare utilisation in all 10 years prior to diagnosis compared to controls without endometriosis — across both primary and secondary care. (pubmed.ncbi.nlm.nih.gov) A 2025 follow-up (same group) used ICD-10 chapter-level analysis to show that the excess contacts spanned nearly all diagnostic categories, suggesting diffuse, poorly characterised pre-diagnosis morbidity — not a specific symptom cluster. (pubmed.ncbi.nlm.nih.gov) These are the most comprehensive quantifications of the diagnostic delay burden available for Denmark.

Incidence: temporal and regional variation

A 2022 population-based study (Illum et al., Acta Obstet Gynecol Scand) found significant temporal and regional differences in hospital-diagnosed endometriosis incidence across Denmark, linked to varying awareness, socioeconomic factors, distance to specialised referral centres and diagnostic capacity. (pubmed.ncbi.nlm.nih.gov) This is direct evidence that "incidence" in registry data is partly a measure of diagnostic access — a critical caveat for any trend analysis.

Obstetric and perinatal outcomes

Using the DNPR linked to the Medical Birth Registry:

  • Preterm birth: Women with endometriosis had higher risk of preterm birth across multiple gestational-age categories, with distinct pathways (spontaneous preterm labour, PPROM, and medically indicated). (pubmed.ncbi.nlm.nih.gov) (Breintoft et al. 2022, Aarhus Birth Cohort, n = large DK singleton cohort.)
  • Pregnancy complications: Women with endometriosis had elevated risk of pre-eclampsia, caesarean section, postpartum haemorrhage, preterm birth and small-for-gestational-age, even after adjusting for fertility treatment. (pubmed.ncbi.nlm.nih.gov) (Glavind et al. 2017, Aarhus Birth Cohort, n = 82,793 pregnancies.)

Mental health burden

A 2026 registry-based study (Josiasen et al., Human Reproduction) quantified antidepressant and anxiolytic prescriptions and psychiatric hospital contacts in women with and without endometriosis. Women with endometriosis redeemed more prescriptions for antidepressants and anxiolytics both before and after the endometriosis diagnosis, and had more psychiatric contacts for depression and anxiety. (pubmed.ncbi.nlm.nih.gov) The pre- diagnosis excess mirrors the healthcare-utilisation pattern and suggests that mental health burden is part of the uncharacterised pre-diagnostic period, not merely a consequence of receiving the diagnosis.

Underutilisation and opportunity

The weekly digest (2026-09-01) notes that Denmark's national registries are "among the world's best for population-scale endometriosis research — barely used for this disease." The recent work cited above (2022–2026) represents a growing but still thin evidence base relative to the registry infrastructure available. Key open questions include:

  • Long-term systemic comorbidities (cardiovascular, autoimmune) with registry ascertainment
  • Pharmacoepidemiology of GnRH antagonist and progestin treatment patterns at population scale
  • Linkage to biobank data (DBDS, Danish Blood Donor Study) for -omics integration
  • Socioeconomic stratification of diagnostic delay and care access
  • Nordic cross-registry cohorts (Denmark + Sweden/Norway/Finland linkage via NOMESKO protocols)

Relevance to OpenEndo

The OpenEndo agenda explicitly includes a registry and EHR analytics workstream (high impact). The Danish registry infrastructure is the primary entry point because:

  1. Code validity has been recently established (Thomsen 2025 PPV study)
  2. Key outcome associations (obstetric, psychiatric, pre-diagnostic utilisation) are mapped
  3. Linkage to the Prescription Register enables treatment-outcome studies at zero recruitment cost
  4. CPR-based linkage eliminates loss-to-follow-up for long-term studies
  5. Nordic collaboration potential amplifies sample size for rare outcomes

OpenEndo's data pipeline should track new DNPR-based endometriosis studies (weekly PubMed search: "endometriosis[tiab] AND Denmark[tiab]") and flag registry study metadata (sample size, registers used, PPV applied) for the living evidence synthesis.

Related pages

Sources

PMID Authors Year Title
40795622 Thomsen et al. 2025 Validation of endometriosis diagnosis code in DNPR 1995-2018 (Eur J Obstet Gynecol)
35434780 Illum et al. 2022 Temporal and regional differences in incidence of hospital-diagnosed endometriosis in Denmark (AOGS)
39704775 Melgaard et al. 2025 Pre-diagnosis hospital contacts using ICD-10: Danish case-control (Human Reprod)
37581901 Melgaard et al. 2023 Healthcare utilisation prior to endometriosis diagnosis: Danish case-control (Human Reprod)
42295201 Josiasen et al. 2026 Endometriosis and mental health burden: registry-based prescriptions + psychiatric contacts (Human Reprod)
35218204 Breintoft et al. 2022 Endometriosis and preterm birth: Danish cohort study (AOGS)
27743699 Glavind et al. 2017 Endometriosis and pregnancy complications: Danish cohort study (Fertil Steril)
Open the source page
Comparisonshigh confidence

Ryeqo vs Yselty

Updated 2026-09-02

Both are oral GnRH-antagonists approved in the EU for second-line symptomatic endometriosis (previous medical or surgical treatment). See GnRH antagonists for endometriosis.

Dimension Ryeqo (relugolix combo) Yselty (linzagolix)
EU approval, endometriosis Nov 2023 Dec 2024
Add-back Built into the pill (40+1+0.5 mg) Separate tablet; 200 mg + add-back required for the endometriosis indication
Evidence SPIRIT 1+2 (n=1,261) EDELWEISS 3+6 (n=484)
Dysmenorrhea responders ~75% vs ~27% placebo (24 wks) 72.9% vs 23.5% at month 3; 91.0% at month 12 (200 mg + ABT)
No-hormone option No Not for endometriosis — 100 mg-no-ABT flexibility is fibroid-label only (75 mg trial arm not a marketed dose)
DK access Generelt tilskud, pharmacy-stocked No general reimbursement for endometriosis (fibroid-only clause); specialist prescription, NBS
DK cost ~33–35 DKK/day (reimbursed) Full price out-of-pocket (DK list price not published; UK ~£1,100/yr)

Verdict

For a Danish endometriosis patient today: Ryeqo is the practical choice — approved, reimbursed, stocked. Yselty is the specialist conversation for women who cannot use an add-back-containing GnRH-antagonist — but note the label requires add-back at the endometriosis dose, so the "no-hormone" argument for choosing Yselty is weaker than often assumed. If Yselty is pursued, expect full price or a regional enkelttilskud application, and verify pharmacy stock. England's NICE (TA1067) lists linzagolix as an option. (nice.org.uk)

Related

Ryeqo (relugolix combination) · Yselty (linzagolix) · GnRH antagonists for endometriosis

Open the source page

Browse the knowledge index